Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate
- 25 May 2022
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (9) , 4440-4448
Abstract
Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir for the treatment of chronic hepatitis B (CHB) infection. We aimed to evaluate the impact of switching to TAF on alanine aminotransferase (ALT) normalization and renal safety. We also described the indications of switching to TAF. Consecutive adult CHB patients switched from tenofovir disoproxil fumarate (TDF) dominant therapy to TAF for more than 12 months were identified retrospectively. A subgroup of patients newly switched to TAF was prospectively invited to perform transient elastography examination and dual‐energy X‐ray absorptiometry. The time of switching to TAF was defined as baseline. Among 393 patients in the retrospective cohort, the median ALT at month 12 was significantly lower (21.0 [16.0–29.9] U/L vs. 25.0 [19.0–34.0] U/L; p < 0.001) and ALT normalization rate was higher (89.9% vs. 83.7%; p = 0.037) than those at baseline. Estimated glomerular filtration rate decreased from 12 months before baseline and then increased from baseline to month 12 significantly (69.7 ± 22.0 ml/min/1.73 m2 vs. 68.5 ± 21.5 ml/min/1.73 m2 vs. 69.2 ± 21.5 ml/min/1.73 m2, p = 0.002 (−12 m vs. baseline), p = 0.004 (baseline vs. 12 m)). In the prospective cohort, 103 patients switched to TAF because of age > 60 years (63.1%), bone diseases (54.4%), and renal alteration (42.7%). TAF is associated with ALT improvement and better renal safety than TDF dominant therapy in CHB patients. Most CHB patients switched to TAF because of advanced age, followed by bone disease and renal alteration.Keywords
Funding Information
- Gilead Sciences
This publication has 26 references indexed in Scilit:
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysisAlimentary Pharmacology & Therapeutics, 2017
- Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosisExpert Review of Gastroenterology & Hepatology, 2017
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateHepatology International, 2015
- Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus TherapyAntimicrobial Agents and Chemotherapy, 2015
- Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infectionJournal of Hepatology, 2015
- Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosisHepatology, 2013
- Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionHepatology, 2012
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009